Date: 2015-06-16
Type of information: Nomination
Compound:
Company: Aegerion Pharmaceuticals (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
Type agreement:
Action mechanism:
Disease:
Details: * On June 16, 2015, Aegerion Pharmaceuticals announced key new hires in the medical affairs and drug safety functions. Jerome Premmereur, MD, joins Aegerion as Vice President, Global Head of Medical Affairs. Dr. Premmereur was previously senior safety leader at Novartis Vaccines. He has more than 20 years of experience in pharmaceutical development, the last 10 of which were dedicated to global medical affairs including in the areas of thrombosis, cardiology, metabolism and oncology.
Sam Yonren, MD, joins Aegerion as Vice President, Global Head of Drug Safety. Dr. Yonren previously led global pharmacovigilance at Seattle Genetics. He has managed product safety with regulators in North America, Europe and Japan, while overseeing post-marketing activities in various therapeutic areas.
Financial terms:
Latest news:
